Bioverge

David Kirn, Co-Founder and CEO of 4DMT, sits down with Neil to discuss the limits of existing AAV vectors and how his company is using its Therapeutic Vector Evolution platform to invent customized vectors that allows it to take a disease specific approach to unlock the potential of genetic medicines.

Peter Kolchinsky, Founder and Managing Director of RA Capital Management and Founder of the nonprofit No Patient Left Behind, sits down with Neil to discuss his book “The Great American Drug Deal,” policy fights over pricing, and his organization’s efforts to make medicines affordable for all Americans.

Kriya Therapeutics Co-Founder, Chairman, and CEO Shankar Ramaswamy sits down with Neil. He discusses how the company is changing the way gene therapies are designed, developed, and manufactured in an effort to cut costs, accelerate the time to market, and expand the reach of gene therapies to a broad universe of disease.

Francisco Gimenez, a member of the 8VC investment team, sits down with Neil to discuss how his background in data science and bioinformatics shapes his investment approach and the potential to transform drug development with technology.

D.A. Wallach sits down with Neil to discuss his journey from recording artists to venture investors, his co-founding of Time BioVentures, and his vision from transforming biotechnology and healthcare with technology.

Daniel Dornbusch, CEO of Excision BioTherapeutics, sits down with Neil to discuss his company’s efforts to develop CRISPR-based therapies to cure HIV and other viral infectious diseases.

Khosla Ventures Partner Gwen Cheni sits down with Neil to talk her migration from Wall Street to early-stage TechBio companies, how that has shaped her investment approach in start-ups, and what emerging technologies excite her today.

Ramsey Homsany, co-founder and president of Octant Bio, sits down with Neil to discuss the company’s efforts to tackle complex diseases with next-generation small molecule drugs by harnessing synthetic biology to better understand the biochemical mechanisms of its targets, his unusual path to leadership of a biotechnology company, and Octant’s collaboration with Bristol Myers Squibb to apply its platform technologies to a set of inflammation-related pathways.

On this episode, David Fajgenbaum, co-founder of Every Cure, sits down with Neil to discuss his new nonprofit, which is seeking to unlock the potential of already approved drugs to treat diseases for which they have not been approved. Fajgenbuam, co-founder and executive director of the Castleman Disease Collaborative Network and assistant professor of medicine at the University of Pennsylvania, recounts the story in his book Chasing My Cure and how he saved his own life by finding a drug to repurpose to treat his rare disease.

Joseph Antoun, CEO of L-Nutra, sits down with Neil to discuss how his company is using state-of-the art science and randomized, placebo-controlled clinical studies to use diet to extend healthy lifespans and treat a wide range of diseases.